Back to News
Market Impact: 0.4
Matinas BioPharma Receives NYSE American Non-Compliance Notice
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Matinas BioPharma received an NYSE American notice that it is not compliant with the exchange's continued-listing requirement to maintain at least $2.0 million in stockholders' equity. The notice raises delisting risk unless the biopharmaceutical company restores compliance, creating a material negative overhang for MTNB shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
MTNB-0.75
More News
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- PG&E’s CEO says AI is ‘the best thing that could’ve ever happened to the grid’
- Defense giant Saab sees orders triple after Gripen fighter jet deal with Ukraine
- Volvo Cars shares plunge 25% amid China sales slump and fresh job cuts
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Eni Raises Investor Payouts as High Fuel Prices Boost Cash Flow